How much has Transcarent raised?
Transcarent has Approximately $450M, with latest valuation/status listed as $2.2B valuation in May 2024 Series D. The important read is not just the headline number but what the money is meant to fund: product depth, enterprise readiness, hiring, and market expansion.
- Total raised
- Approximately $450M
- Disclosed rounds
- 4 major disclosed/reported events
- Latest round
- Series D — $126M at $2.2B valuation
- Latest valuation
- $2.2B valuation in May 2024 Series D
- First raised
- October 2020
- Notable backer
- General Catalyst and 7wireVentures led; total funding reached approximately $450M
Transcarent's funding rounds
Transcarent's capital history shows how investor appetite has tracked product-market pull and category timing.
- October 2020Series A — $40MEarly financing for Transcarent's consumer-directed health platform.
- June 2021Series B — $58MRound brought total funding to $98M.
- 2022Series C — amount not fully repeated in latest releaseSeries C brought the company above unicorn status with health-system and investor participation.
- May 2024Series D — $126M at $2.2B valuationGeneral Catalyst and 7wireVentures led; total funding reached approximately $450M.
How much has Transcarent raised in total?
Transcarent has Approximately $450M. The profile separates confirmed company announcements from third-party private-market estimates when the company has not disclosed a full cap table or valuation.
Who are Transcarent's investors?
The named investors and round leads are captured in the funding timeline above. For undisclosed rounds, use the latest public investor names as directional signals rather than assuming every prior backer participated pro rata.
Why did the valuation move?
The valuation moved with the company's category momentum, scale, and investor demand. Where the latest valuation is undisclosed, the absence of a mark matters: sellers should anchor on operating scale and budget signals rather than a guessed number.
Is Transcarent profitable, and will it IPO?
Transcarent has not publicly provided enough information to make a profitability call unless noted in the sources. There is no announced IPO date, so IPO timing should be treated as speculative.
What does Transcarent's funding mean if you sell into them?
Recent financing usually creates budget for leadership hiring, security, compliance, infrastructure, data, finance systems, recruiting, and enterprise go-to-market. The best outreach angle is tied to the round's stated use of proceeds and the operational bottlenecks created by rapid growth.
As of June 2026.Sources:Transcarent homepageTranscarent leadershipTranscarent Series DTranscarent careers
Transcarent — frequently asked questions
